These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7479466)

  • 41. Effect of salmon calcitonin on symptoms and urinary excretion of 5 hydroxyindoleacetic acid in the carcinoid syndrome.
    Antonelli A; Del Guerra P; Fierabracci A; Gori E; Baschieri L
    Br Med J (Clin Res Ed); 1987 Oct; 295(6604):961. PubMed ID: 2445410
    [No Abstract]   [Full Text] [Related]  

  • 42. Ghost carcinoid in a patient with 120-fold elevated 5-hydroxyindoacetic acid.
    Yu R; Wolin E
    Endocr Pract; 2012; 18(5):803-4. PubMed ID: 23047932
    [No Abstract]   [Full Text] [Related]  

  • 43. Biochemical detection of phaeochromocytoma: should we still be measuring urinary HMMA?
    Peaston RT; Lai LC
    J Clin Pathol; 1993 Aug; 46(8):734-7. PubMed ID: 8408698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
    Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
    Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous assay for urinary 4-hydroxy-3-methoxy-mandelic acid, 5-hydroxyindoleacetic acid and homovanillic acid by isocratic HPLC with electrochemical detection.
    Davidson DF
    Ann Clin Biochem; 1989 Mar; 26 ( Pt 2)():137-43. PubMed ID: 2471433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinguishing features of idiopathic flushing and carcinoid syndrome.
    Aldrich LB; Moattari AR; Vinik AI
    Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The carcinoid syndrome: An example due to an ileal polyp.
    Orr KB
    Aust N Z J Surg; 1970 Feb; 39(3):268-72. PubMed ID: 4192147
    [No Abstract]   [Full Text] [Related]  

  • 48. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary excretion of 5-hydroxy-3-indoleacetic acid in dystimic/depressed, adult obese women: what correlations to hepatic steatosis?
    Tarantino G; Savastano S; Colao A; Polichetti G; Capone D
    Int J Immunopathol Pharmacol; 2011; 24(3):769-79. PubMed ID: 21978708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carcinoid tumors of the pancreas. Status report based on two cases and review of the world's literature.
    Mao C; el Attar A; Domenico DR; Kim K; Howard JM
    Int J Pancreatol; 1998 Apr; 23(2):153-64. PubMed ID: 9629513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
    Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
    Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of 5-hydroxyindoleacetic acid in urine by high-performance liquid chromatography: a fully automated method.
    Garnier JP; Bousquet B; Dreux C
    J Chromatogr; 1981 Jan; 204():225-30. PubMed ID: 6163791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
    Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
    Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measurement of plasma 5-hydroxyindoleacetic acid in carcinoid disease: an alternative to 24-h urine collections?
    Degg TJ; Allen KR; Barth JH
    Ann Clin Biochem; 2000 Sep; 37 ( Pt 5)():724-6. PubMed ID: 11026528
    [No Abstract]   [Full Text] [Related]  

  • 57. An improved method for the estimation of urinary 5-hydroxyindole-acetic acid and its application to the diagnosis of carcinoidosis.
    Humbel R
    Clin Chim Acta; 1973 Feb; 43(3):453-5. PubMed ID: 4690917
    [No Abstract]   [Full Text] [Related]  

  • 58. [Detection and biochemical exploration of carcinoid tumors].
    Dreux C; Bousquet B; Halter D
    Nouv Presse Med; 1974 Mar; 3(11):671-6. PubMed ID: 4546018
    [No Abstract]   [Full Text] [Related]  

  • 59. Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data.
    Harris AG; Redfern JS
    Aliment Pharmacol Ther; 1995 Aug; 9(4):387-94. PubMed ID: 8527614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac manifestations in mid-gut carcinoid disease.
    Jacobsen MB; Nitter-Hauge S; Bryde PE; Hanssen LE
    Eur Heart J; 1995 Feb; 16(2):263-8. PubMed ID: 7538079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.